Literature DB >> 21161448

Extreme insulin resistance: indications and approaches to the use of U-500 insulin in type 2 diabetes mellitus.

Alexandria M Dailey1, Lisa R Tannock.   

Abstract

The use of U-500 insulin in the management of highly insulin resistant diabetic patients is growing. There are a number of reports that have noted the effects of U-500 insulin using multiple daily injections or continuous subcutaneous insulin infusion on hemoglobin A(1c), weight, and total daily insulin dosage. The effect of U-500 insulin use on glycemic control, changes in body weight, total daily insulin dosage, incidence of hypoglycemia, and effect on lipid levels and blood pressure as well as patient satisfaction and quality of life will be reviewed. In addition, this article will delineate algorithms of U-500 use, compare multiple daily injections or continuous subcutaneous insulin infusion, and discuss U-500 insulin pharmacokinetics.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21161448     DOI: 10.1007/s11892-010-0167-6

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  18 in total

Review 1.  The use of U-500 in patients with extreme insulin resistance.

Authors:  Elaine Cochran; Carla Musso; Phillip Gorden
Journal:  Diabetes Care       Date:  2005-05       Impact factor: 19.112

2.  Use of U-500 regular insulin in type 2 diabetes.

Authors:  Wafic S Wafa; Mukhtar I Khan
Journal:  Diabetes Care       Date:  2006-09       Impact factor: 19.112

3.  Clinical experience with U-500 regular insulin in obese, markedly insulin-resistant type 2 diabetic patients.

Authors:  Piya Ballani; Michael T Tran; Maria D Navar; Mayer B Davidson
Journal:  Diabetes Care       Date:  2006-11       Impact factor: 19.112

4.  U-500 insulin: why, when and how to use in clinical practice.

Authors:  R Garg; V Johnston; P G McNally; M J Davies; I G Lawrence
Journal:  Diabetes Metab Res Rev       Date:  2007-05       Impact factor: 4.876

5.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

Authors:  David M Nathan; Patricia A Cleary; Jye-Yu C Backlund; Saul M Genuth; John M Lachin; Trevor J Orchard; Philip Raskin; Bernard Zinman
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

6.  Use of U-500 regular insulin by continuous subcutaneous insulin infusion in patients with type 2 diabetes and severe insulin resistance.

Authors:  Wendy S Lane
Journal:  Endocr Pract       Date:  2006 May-Jun       Impact factor: 3.443

7.  Clinical efficacy and patient satisfaction with U-500 insulin use.

Authors:  Alexandria M Dailey; Sarah Williams; Deepa Taneja; Lisa R Tannock
Journal:  Diabetes Res Clin Pract       Date:  2010-03-11       Impact factor: 5.602

8.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

9.  Clinical efficacy and patient satisfaction with U-500 insulin pump therapy in patients with type 2 diabetes.

Authors:  Deepti G Bulchandani; Tara Konrady; Mitchell S Hamburg
Journal:  Endocr Pract       Date:  2007 Nov-Dec       Impact factor: 3.443

10.  U-500 regular insulin: clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetic patients.

Authors:  Mayer B Davidson; Maria D Navar; Diana Echeverry; Petra Duran
Journal:  Diabetes Care       Date:  2009-11-12       Impact factor: 19.112

View more
  5 in total

Review 1.  Clinical use of U-500 regular insulin: review and meta-analysis.

Authors:  Sirimon Reutrakul; Kristen Wroblewski; Rebecca L Brown
Journal:  J Diabetes Sci Technol       Date:  2012-03-01

2.  Durability of glycemic control using U-500 insulin.

Authors:  Alexandria M Dailey; Jennifer A Gibert; Lisa R Tannock
Journal:  Diabetes Res Clin Pract       Date:  2011-11-15       Impact factor: 5.602

3.  Clinical Impact of Initiation of U-500 Insulin vs Continuation of U-100 Insulin in Subjects With Diabetes.

Authors:  Alejandro Ramirez; Natalia Weare-Regales; Anthony Domingo; Arnaldo Villafranca; Krystal A Valdez; C Marcela Velez; Philip Foulis; Joaquin Gomez-Daspet
Journal:  Fed Pract       Date:  2021-03

4.  Translating U-500R Randomized Clinical Trial Evidence to the Practice Setting: A Diabetes Educator/Expert Prescriber Team Approach.

Authors:  Paula M Bergen; Davida F Kruger; April D Taylor; Wael E Eid; Arti Bhan; Jeffrey A Jackson
Journal:  Diabetes Educ       Date:  2017-04-21       Impact factor: 2.140

5.  Development and Implementation of a U-500 Regular Insulin Program in a Federally Qualified Health Center.

Authors:  Kathy F Shaw; Connie A Valdez
Journal:  Clin Diabetes       Date:  2017-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.